Canada · Delayed Price · Currency is CAD Rakovina Therapeutics Company Description
Rakovina Therapeutics Inc., a biopharmaceutical research company, engages in the research and development of cancer treatments that target DNA-damage response systems.
It develops kt-2000 series, which are patented class of oral, small molecule PARP inhibitors with established in vitro and in vivo proof of concept; kt-3000 series drug candidates, which are bi-functional targeted small molecules designed to inhibit both PARP and histone deacetylase; and kt-4000 series, which are small molecules engineered to induce targeted DNA damage in tumor cells.
The company is also involved in the development of kt-5000 series of brain-penetrant dual ATR–mTOR inhibitor drug candidates.
It has a strategic collaboration with Variational AI Inc. to develop AI-generated ATR inhibitor compounds; and a non-binding Letter of Intent to form a joint venture to co-develop AI-discovered small-molecule oncology therapies.
The company was formerly known as Vincero Capital Corp. Rakovina Therapeutics Inc. is headquartered in Vancouver, Canada.
| Country | Canada |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Kim Oishi |
Contact Details
Address: 999 West Broadway Vancouver, BC V5Z 1K5 Canada | |
| Website | rakovinatherapeutics.com |
Stock Details
| Ticker Symbol | RKV |
| Exchange | TSX Venture Exchange |
| Fiscal Year | January - December |
| Reporting Currency | CAD |
| ISIN Number | CA75103L1013 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Kim Oishi | Chief Executive Officer and Director |
| Dr. Mads Daugaard Ph.D. | President and Chief Scientific Officer |
| Dr. John Langlands Ph.D. | Chief Operating Officer |
| Dr. David M. Kideckel M.B.A., Ph.D. | Chief Financial Officer and Director |
| Michelle Seltenrich M.B.A. | Director of Corporate Development |